ClinicalTrials.gg
Active, not recruitingNCT05371041Updated Sep 25, 2026Results posted

Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression

An interventional study of Medtronic Percept Neurostimulator in Tourette Syndrome, sponsored by University of Florida. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by University of Florida · Not applicable, Interventional, and Device feasibility

How we know

Updated Sep 25, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
90th of 105
8 · median 33
Started
2022
with 6 others
No phase
48 of 139
10 open now
Primary completion
2026-05
later than 5 of 23 live
Registered
120th of 139
by date
Lead sponsor
8 of 139
University of Florida

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 90th largest by enrollment of the 105 interventional ones that give a count, is one of 7 that started in 2022, is one of 48 with no phase, reaches primary completion later than 5 of the 23 other live ones, and was the 120th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

The investigators will implant and monitor 8 research subjects with a subcortical closed-loop system for detection and suppression of tics in subjects with medically refractory debilitating Tourette Syndrome. The project will use the FDA-approved "Medtronic Percept PC" device, which is an implantable neurostimulator capable of recording neural signals. The study will target the CM nucleus of the thalamus and the aGPi in each brain hemisphere from each subject and we will connect the two leads placed in each brain hemisphere to two Percept devices.

Read the detailed description

Tourette syndrome (TS) is a continuous lifelong condition that is highly prevalent, socially disabling, and in some severe cases, physically injurious. Deep Brain Stimulation (DBS) has emerged as a promising treatment option for addressing uncontrollable tics in medically refractory, severe cases of TS frequently involving self-injurious behavior. We have undertaken a major informatics initiative by establishing the International TS DBS Registry and Database, a multi-country consortium that has captured long term outcomes of 277 TS DBS patients representing 50-75% of all TS DBS cases worldwide. From these outcomes, two deep brain targets have emerged as potentially effective: the centromedian nucleus region (CM) of the thalamus, and the anterior globus pallidus internus (aGPi). However, our current understanding of tic generation is limited by many factors including a lack of animal models for TS, apparently normal brain structure on structural imaging, and the impracticality of studying involuntary motor tics with functional imaging. Next generation closed-loop DBS systems can record brain activity in patients with TS and identify the neurophysiological correlates of tics. Moreover, these devices can deliver stimulation in response to a patient's symptomatic state. Our overall goal is to develop neurophysiology driven and connectivity-guided closed-loop DBS systems for the improved treatment of TS. To this end, we will implant 8 medically resistant TS patients with bilateral leads in the CM and aGPi. In Aim 1, we will identify structural network projections from CM and aGPi to guide pre-operative surgical planning and post-operative selection of stimulation parameters. In Aim 2, we will identify neurophysiologic correlates of tic genesis in the CM and aGPi. We will also study thalamo-pallidal network interactions leading to and during tics. In Aim 3, we will test the feasibility, safety, and efficacy of closed-loop TS DBS. We expect that closed-loop stimulation will provide more effective and personalized treatment options with longer battery life and fewer adverse effects than traditional chronic stimulation.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The diagnosis of TS must be made by both a fellowship-trained movement disorders neurologist and a psychiatrist and must meet (DSM-V) criteria for a diagnosis of TS.
  • Yale Global Tic Severity Scale (YGTSS; 100) must be >35/50 and the motor tic sub score >15. The TS must be causing incapacitation with severe distress, self-injurious behavior, and/or quality of life disruption. OCD, Depression, and ADHD are not exclusionary provided tics are the major difficulty requiring surgical intervention.
  • There are no gender criteria for this study.
  • The subject's TS symptoms must be medication . To meet the medication refractory criteria, subjects must have been treated by a psychiatrist or neurologist experienced in TS with therapeutic doses (doses adapted from Scahill's recommendations of at least three dopamine blocking drugs) [either 1-4 mg/day of haloperidol, 2-8 mg/day of pimozide, risperidone (1-3 mg/day), or aripiprazole (2.5-5 mg/day)]. There must be at a minimum7 single trial with an alpha-2 adrenergic agonist (0.1-0.3 mg/day).
  • depression if present must be pharmacologically treated and deemed stable (by the study psychiatrist).
  • Must have been stabilized for one month on TS medication without a dose change prior to surgical intervention. If medication trials resulted in discontinuation of TS medications, the subject must be stabilized for three months off TS medicines.
  • Must be willing to keep TS related medications stable and unchanged throughout the trial.
  • Must have been offered habit reversal therapy/cognitive behavioral intervention therapy (HRT) if a subject did not have it prior to enrollment. Subjects are not required to participate in HRT but it will be highly encouraged, and must be completed prior to the start of the protocol. Those who improve significantly with HRT will be excluded from receiving surgery.
  • If the tic is focal or addressable by botulinum toxin treatment, the study neurologist will offer to administer a trial of botulinum toxin prior to consideration of surgical therapy. If the subject chooses not to have the treatment, they cannot participate in the study. If the subject responds satisfactorily to botulinum toxin, and their quality of life significantly improves, they will be excluded from the study.
  • Must be 18 years of age or older.8

Exclusion criteria

Exclusion Criteria:

    • Any previous neurosurgical intervention such as DBS or ablative brain lesions. Participants with previous DBS system that have been explanted will still be excluded from the study.

      • Any metal in the body that would preclude the patient from receiving an MRI scan.
      • Untreated or unstable anxiety, depression, bipolar disorder or other Axis I psychiatric disorder.
      • Presence of psychotic features.
      • Significant psychosocial factors that may impart an increased risk.
      • The presence of only simple motor tics, a movement disorder other than TS, or medication related movement disorders from TS medications.
      • The presence of drug-induced tics (potentially associated with the use of stimulant medications, anticonvulsant drugs, etc.).
      • Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney disease, chronic neurological disease, hematological disease, or frailty that impact tolerability of the surgery as judged by the screening physicians.
      • Abnormal brain magnetic resonance imaging (MRI) scan including hydrocephalus, stroke, structural lesions, demyelinating lesions, or infectious lesions that would potentially confound the outcome or safety of the surgery as judged by the study neurosurgeon. Also excluded if severe atrophy is present on the brain scan.
      • Dementia or cognitive dysfunction that will place the subject at risk for worsening cognition, and/or may impact the ability to cooperate with tasks involved in the study.
      • Any attempt or intent of suicide in the last six months.
      • Significant substance abuse or dependence (e.g., stimulants, alcohol, opiates, benzodiazepines) within the past six months.
      • A positive urine drug screen for illicit substances (a urine drug screen is required), not to include marijuana/cannabinoid use.
      • Patients who do not have access to a site that can program the device if they cannot come to The University of Florida for clinical re-programming follow-up appointments after completion of the study.
      • Multiple failed medication treatments of inadequate dose or duration.
      • History of noncompliance with previous medical and psychosocial treatment efforts.
      • Severe head banging tics (any tics which have the potential to result in damage to the DBS as judged by the neurosurgeon).
      • Women of who are pregnant or who wish to become pregnant during the study (a urine pregnancy screen required).
      • History of multiple surgical procedures with poor outcomes.
      • Unexplained gaps in medical history.
      • Pending lawsuits or other legal action.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Medtronic Percept Neurostimulator

    This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.

    Device: Medtronic Percept Neurostimulator

Interventions

  • DeviceMedtronic Percept Neurostimulator

    This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.

06

What researchers measure

Primary outcomes

  1. Yale Global Tic Severity Scale_(YGTSS) - Total Tic Score

    The YGTSS is a clinician-rated scale used to assess tic severity over the prior week. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics - scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impairment dimension scored from 0 to 50. The Total Tic Score (YGTSS-TTS) was used in these analyses.

    Time frame: 9 months

07

Results

Posted Sep 25, 2026

Participant flow

Study subjects were recruited through the Tourette Association of America network of physicians and the University of Florida Neurology clinical setting.

Participant flow — Overall Study
Milestone9 Month Primary Outcome
Started8
Completed8
Not completed0

Outcome measures

PrimaryYale Global Tic Severity Scale_(YGTSS) - Total Tic Score

The YGTSS is a clinician-rated scale used to assess tic severity over the prior week. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics - scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impairment dimension scored from 0 to 50. The Total Tic Score (YGTSS-TTS) was used in these analyses.

Time frame:
9 months
Reported as:
Number · Scores on a scale
Yale Global Tic Severity Scale_(YGTSS) - Total Tic Score
Scores on a scale9 Month Primary Outcome
S117
S241
S323
S481
S538
S647
S76
S810

Adverse events

Collected over from enrollment until end of follow-up (approximately 2 years after lead implant surgery). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
9 Month Primary Outcome0/8 (0%)3/8 (37.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
Event9 Month Primary Outcome
Inpatient hospitalization required for functional (psychogenic) episodes following lead implantationPsychiatric disorders1/8
Superficial microabsess in the area of left scalp incision (post DBS surgery)Skin and subcutaneous tissue disorders1/8
Post-operative hospital stay extended due to hemorrhageNervous system disorders1/8
Most frequent other events
Showing 10 of 20
Most frequent other events
Event9 Month Primary Outcome
AnxietyPsychiatric disorders3/8
Nausea and VomitingGastrointestinal disorders2/8
Device tethering / neurostimulator connection errorSkin and subcutaneous tissue disorders1/8
DepressionPsychiatric disorders1/8
Skin IrritationSkin and subcutaneous tissue disorders1/8
General MalaiseGeneral disorders1/8
InfluenzaRespiratory, thoracic and mediastinal disorders1/8
Transient Chest PainCardiac disorders1/8
Facial swelling post surgeryGeneral disorders1/8
Transient Panic attackPsychiatric disorders1/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Medtronic Percept Neurostimulator
<=18 years2
Between 18 and 65 years6
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Medtronic Percept Neurostimulator
Female7
Male1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Medtronic Percept Neurostimulator
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Medtronic Percept Neurostimulator
Hispanic or Latino0
Not Hispanic or Latino8
Unknown or Not Reported0
YGTSS Score
YGTSS Score(Scores on a scale)Medtronic Percept Neurostimulator
S194
S296
S394
S491
S587
S687
S778
S884
08

Study locations

1 site
  • Norman Fixel Institute for Neurological Diseases - University of Florida
    Gainesville, Florida 32608, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in May 2026, 46 months.

Results were first posted in Sep 2026, 4 months after primary completion.

Of 65 non-industry interventional studies with no phase under Tourette Syndrome, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's 46 months is above that.

Counting every sponsor, half of 65 studies reached it within 33 months; a quarter within 22 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Aug 2026 → May 2026 and completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2022
First posted
May 12, 2022
StartActual
Jun 20, 2022
Primary completionActual
May 1, 2026was Aug 2026
CompletionEst.
Aug 31, 2027was Aug 2026
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 25, 2026
Primary completion
Aug 31, 2026→May 1, 2026 (actual)
Sep 25, 2026
Study completion
Aug 31, 2026→Aug 31, 2027
Sep 25, 2026
Documents
Show all 1 update
  1. Sep 25, 2026
    Results posted
    Primary completion Aug 31, 2026→May 1, 2026 (now actual)
    Study completion Aug 31, 2026→Aug 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05371041
Responsible party
Sponsor
First posted
May 12, 2022
Start date
Jun 20, 2022
Primary completion
May 1, 2026
Completion
Aug 31, 2027 (estimated)
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Michael Okun, MD
principal investigator · University of Florida
Christopher Butson, PhD
principal investigator · University of Florida
Aysegul Gunduz, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion